This was a prospective, randomized, open-label, blinded end point (PROBE), 30 parallel group study with two treatment arms. A total of 160 outpatients aged 61–75 years entered a 2-week wash-out period ...

Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease -13.17 mmol/L ...